
|Videos|February 1, 2023
KRASG12C Mutations and CNS Metastases in Patients with NSCLC
Author(s)Mark Socinski, MD, Joshua K. Sabari, MD
Drs Socinski and Sabari discuss the emergence of the KRAS12C mutation, specifically in patients with CNS metastases and how this factors into their treatment decision.
Advertisement
Episodes in this series

Advertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Accepts BLA for Ivonescimab in Pretreated EGFR-Mutated NSCLC
2
The Targeted Pulse: New Standards in Myeloma, Melanoma, and More
3
Onvansertib Triplet Shows Dose-Dependent Frontline Benefit in RAS-Mutant Metastatic CRC
4
Pembrolizumab/Lenvatinib Show Efficacy, Safety in Clear Cell Gyn Cancers
5



















